Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CareCN gene therapy study in severe Crigler-Najjar syndrome
2023-507007-60-00Phase 2Authorised
- Sponsor
- Généthon
- Start
- Apr 2018
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of GNT-0003 in Crigler-Najjar syndrome (CNS), sponsored by Généthon. Planned start Apr 2018; status: authorised.
02
Drugs
GNT-0003
03
Conditions
Crigler-Najjar syndrome (CNS)
Beyond the preview
Go deeper on 2023-507007-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507007-60-00.